Tazarotene

Topical Retinoid
Compare To Other Treatments

The following side effects are expected to occur with the first few weeks of using of tazarotene. Contact your doctor if these symptoms are severe and/or do not go away:

How Common (based on clinical studies)

Skin peeling or scalingUp to 40% of all users
Redness and/or warmth in the areaUp to 34% of all users
Skin irritation, burning, stinging, or tingling sensationsUp to 26% of all users
Dry skinUp to 27% of all users
ItchingUp to 10% of all users
Swelling and inflammationUp to 8% of all users
RashUp to 3% of all users
Increased skin oilinessUp to 2% of all users
Pain in the areaUp to 1.2% of all users
Inflamed or chapped lipsUp to 1% of all users
Increased sensitivity to UV rays (photosensitivity)Up to 1% of all users
Swelling and irritation of the eye or eyelidUnknown
Swelling over the arms or legsUnknown
Skin discolorationUnknown

Tazarotene may also cause other side effects that are not mentioned here. Contact your doctor if you experience any other troublesome symptoms when using tazarotene.

References
  1. Up to date; Tazarotene. Available from: https://www.uptodate.com/contents/tazarotene-drug-information?source=search_result&search=tazarotene&selectedTitle=1~29. Cited 4 January 2017.
  2. Bershad, S., et al. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch. Dermatol. 138(4), 481-489 (2002).
  3. Saple, D.G., et al. An open study to evaluate the efficacy and safety of tazarotene gel (0.1%) in acne vulgaris. Indian J. Dermatol. Venereol. Leprol. 70(2), 92-95 (2004).
  4. Shalita, A.R., et al. Effects of tazarotene 0.1% cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. Clin. Ther. 26(11), 1865-1873 (2004).
  5. Feldman, S.R., Werner, C.P., and Aliȯ Saenz A.B. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. J. Drugs Dermatol. 12(4), 438-446 (2013).
  6. Shalita, A., Miller, B., Menter, A., Abramovits, W., Loven, K., and Kakita, L. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. J. Drugs Dermatol. 4(2), 153-158 (2005).
  7. Leyden, J., et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch. Dermatol.142(5), 605-612 (2006).
  8. Tanghetti, E., Abramovits, W., Solomon, B., Loven, K., and Shalita, A. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial. J. Drugs Dermatol. 5(3), 256-261 (2006).
  9. Thiboutot, D., Arsonnaud, S., and Soto, P. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J. Drugs Dermatol. 7(6) suppl, s3-s10 (2008).
  10. Pariser, D., Colon, L.E., Johnson, L.A., and Gottschalk R.W. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris. J. Drugs Dermatol. 7(6) suppl, s18-s23 (2008).
  11. DailyMed. Tazarotene. Available from: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=TAZAROTENE&pagesize=20&page=1. Cited 10 January 2019.